Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CDC7 | O00311 | 10/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 10/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552538 | 0.87 | LMNA (0.36) | NPC1RAB9AALDH1A1HSD17B10HPGD | |
| SCHEMBL404952 | 0.85 | ALDH1A1 (0.58) | NPC1RAB9ACDC7DBF4ALDH1A1 | |
| SCHEMBL404165 | 0.80 | ALDH1A1 (0.41) | CDC7DBF4ALDH1A1HSD17B10MAPT | |
| SCHEMBL1505433 | 0.79 | LMNA (0.48) | CDC7DBF4ALDH1A1HSD17B10MAPT | |
| SCHEMBL401914 | 0.77 | ALDH1A1 (0.40) | CDC7DBF4ALDH1A1HSD17B10MAPT | |
| SCHEMBL3400633 | 0.77 | NOTUM (0.40) | CDC7DBF4ALDH1A1HSD17B10MAPT | |
| SCHEMBL510314 | 0.75 | CDC7 (0.62) | NPC1RAB9ACDC7DBF4ALDH1A1 | |
| SCHEMBL3403482 | 0.75 | LMNA (0.62) | NPC1RAB9ACDC7DBF4ALDH1A1 | |
| SCHEMBL404775 | 0.75 | FBP1 (0.39) | NPC1RAB9ACDC7DBF4ALDH1A1 | |
| SCHEMBL3406836 | 0.74 | CDC7 (0.48) | CDC7DBF4ALDH1A1HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022107-A1 | 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022107-A1 | 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022107-A1 | 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-01-26 | — | — | US | disclosed |
| WO-2010067125-A1 | 2- (PIPERIDIN-1-YL) -4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022107-A1 | 2-(PIPERIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | PIR, TLR5, ALPI | NPC1 1284/4885RAB9A 2126/4885CDC7 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.